RxDoctor Payments Data

Teresa Martone

Family · Pleasantville, NJNPI 1568993806

Payments from drug & device makers

$1,069in general payments, 2019–2025

Across 56 payments — averaging $19.09 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$416
  • Amgen$284
  • Boston Scientific$107
  • Scilex Pharmaceuticals Inc.$71
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$44
  • Collegium Pharmaceutical, Inc.$43
  • plus $105 from 5 others

What the payments were for

  • Food & beverage$1,069100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,069 in reported general payments places this provider in the 75th percentile of 2,692 family providers in New Jersey.

See all family providers in New Jersey

Medicare billing

Part B allowed, 2024
$79,130
Medicare patients
78
Services billed
729

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban77$75,660
JanuviaSitagliptin Phosphate25$19,066
TrulicityDulaglutide11$13,693
MyrbetriqMirabegron14$6,591
Humalog Kwikpen U-100Insulin Lispro13$3,858
Buprenorphine19$3,781
Humulin 70/30 KwikpenInsulin Nph Hum/Reg Insulin Hm21$3,470
Janumet XrSitagliptin Phos/Metformin Hcl12$3,343
Lidocaine17$3,005
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog13$2,963
Albuterol Sulfate HfaAlbuterol Sulfate61$2,894
Lantus SolostarInsulin Glargine,hum.Rec.Anlog19$2,448
Atorvastatin Calcium153$1,558
Famotidine34$1,550
Tolterodine Tartrate ErTolterodine Tartrate13$1,325

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$15$75,66077 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 2,692 family providers in New Jersey.

Other family in Pleasantville

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →